Evaluation of Pneumococcal Vaccine Formulations in Young Adults

Infections, Streptococcal Clinical Trial

Official title:

A Study to Evaluate GSK Biologicals' Candidate Formulations of Pneumococcal Vaccines (GSK2189242A) in Young Adults.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00707798
• Other study ID #: 111651
• Status: Completed
• Phase: Phase 1
• First received: June 30, 2008
• Last updated: May 9, 2017
• Start date: June 30, 2008
• Est. completion date: January 15, 2009

Study information

• Verified date: May 2017
• Source: GlaxoSmithKline
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety, reactogenicity and immunogenicity of pneumococcal vaccines in young adults. Subjects will be vaccinated twice with an interval of two months.

Description:

This amendment was due to

• The addition of secondary endpoints for safety. The collection of data related to these secondary safety endpoints was already planned and the corresponding statistical analyses were described in the statistical section.

• The addition of an exclusion criterion regarding the administration of immunoglobulins and blood products. It is already included in the elimination criteria section. It impacts only immunogenicity.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 157
• Est. completion date: January 15, 2009
• Est. primary completion date: January 15, 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• Subjects who the investigator believes will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits) should be enrolled in the study.

• A male or female between, and including, 18 and 40 years old at the time of the first vaccination.

• Written informed consent obtained from the subject.

• Free of obvious health problems as established by medical history, clinical examination and clinical laboratory assessment before entering into the study.

• If the subject is female, and of child-bearing potential, she agrees to use adequate contraception and not become pregnant for the duration of the study.

Exclusion Criteria:

• Previous vaccination against Streptococcus pneumoniae.

• Vaccination with diphtheria/tetanus toxoids within one month preceding the first dose of study vaccine.

• Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period or participation to another pharmaceutical/vaccine study.

• Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.

• Planned administration/administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of study vaccine, with the exception of the influenza vaccine which can be administered > 7 days preceding or > 7 days following each vaccine dose (after collection of 7-day safety data).

• Bacterial pneumonia within 3 years prior to 1st vaccination.

• Invasive pneumococcal disease (IPD) within 3 years prior to 1st vaccination.

• Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.

• History of thrombocytopenia or bleeding disorder.

• History of reactions or allergic disease likely to be exacerbated by any component of the vaccine.

• Current serious neurologic or mental disorders.

• Inflammatory processes such as known chronic active infections (e.g. Hepatitis B, C).

• All past or current malignancies (excluding non-melanic skin cancer) and lymphoproliferative disorders.

• Acute disease at the time of enrolment/vaccination.

• Physical examination positive for acrocyanosis, jaundice, splenomegaly.

• Acute or chronic, clinically significant anaemia, pulmonary, cardiovascular, hematologic , hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests, at the discretion of the investigator.

• Laboratory evidence of haematological abnormalities.

• Laboratory evidence of biochemical abnormalities

• Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.

• Pregnant or lactating female.

• Female planning to become pregnant or planning to discontinue contraceptive precautions.

• History of chronic alcohol consumption and/or drug abuse.

• Other conditions that the principal investigator judges may interfere with study findings.

Related Conditions & MeSH terms

• Infections, Streptococcal
• Streptococcal Infections

Intervention

Biological:
• Pneumococcal vaccine GSK2189242A
Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2. Six different formulations of this vaccine will be tested
• Pneumo 23™
One dose of 0.5 ml will be administered intramuscularly at Month 0, and a placebo dose to keep the blinding at Month 2

Locations

Country	Name	City	State
Belgium	GSK Investigational Site	Gent

Sponsors (1)

Lead Sponsor	Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrence of any vaccine related and grade 3 solicited local and general adverse events		During a 7-day follow up period after each vaccine dose
Primary	Occurrence of any vaccine related and grade 3 unsolicited adverse events		During a 31-day follow up period after each vaccine dose
Primary	Occurrence of any vaccine related serious adverse events (SAE)		From Visit 1 to study conclusion
Primary	Occurrence of any grade 3 laboratory abnormalities		During a 7-day follow up period after each vaccine dose
Secondary	Occurrence of any solicited local and general adverse events		During a 7-day follow up period after each vaccine dose.
Secondary	Occurrence of any unsolicited adverse events		During a 31-day follow up period after each vaccine dose
Secondary	Occurrence of any haematological, biochemical, or urinary abnormalities		At 1 and 7 days after each vaccine dose
Secondary	Anti-pneumococcal and anti-NTHi candidate vaccine antigens		At Days 0, 30 and 90

External Links

•   Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
•   Results for study 111651 can be found on the GSK Clinical Study Register